Topamax Warning? The Food and Drug Administration issued a "Drug Safety Communication" notifying the public of new evidence demonstrating increased risk for the development of oral birth defects in infants born to women who took Topamax (Topiramate) during pregnancy.

The FDA warns that recently released data has shown that women who took Topamax while pregnant were 21 times more likely to give birth to an infant with oral birth defects, specifically cleft lips or cleft palates. Moreover, women who took Topamax during pregnancy were also prone to birthing infants with other congenital birth defects, including, but not limited to spina bifida, hypospadias, persistent pulmonary hypertension, heart and lung defects, neural defects, and craniofacial defects.